Kevin P. Baker

5.8k total citations · 2 hit papers
27 papers, 3.7k citations indexed

About

Kevin P. Baker is a scholar working on Molecular Biology, Immunology and Rheumatology. According to data from OpenAlex, Kevin P. Baker has authored 27 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 10 papers in Immunology and 5 papers in Rheumatology. Recurrent topics in Kevin P. Baker's work include Fibroblast Growth Factor Research (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (5 papers). Kevin P. Baker is often cited by papers focused on Fibroblast Growth Factor Research (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (5 papers). Kevin P. Baker collaborates with scholars based in United States, Switzerland and United Kingdom. Kevin P. Baker's co-authors include Gottfried Schatz, Viktor Roschke, William I. Wood, Audrey D. Goddard, Daryl T. Baldwin, Scot A. Marsters, Austin Gurney, Robert Pitti, Paul J. Godowski and James P. Sheridan and has published in prestigious journals such as Nature, Science and Journal of Biological Chemistry.

In The Last Decade

Kevin P. Baker

27 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

1997 1.5k citations James P. Sheridan, Scot A. Marsters et al. Science profile →
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus

2001 606 citations Viktor Roschke, Kevin P. Baker et al. The Journal of Immunology profile →

Peers

Kevin P. Baker

IMMUN

RHEUM

RNMI

Bahija Jallal United States

Tatsuo Senshu Japan

Kaihong Su United States

Andréas Tsapis France

Anne B. Satterthwaite United States

Navin Rao United States

Doriana Fruci Italy

Rosaria Orlandi Italy

Claudia Palena United States

Martin Hegen United States

Bahija Jallal United States

Kevin P. Baker

2.6k ×1.3

2.0k ×1.1

IMMUN

1.4k ×1.8

RHEUM

634 ×1.1

707 ×1.3

RNMI

Citations per year, relative to Kevin P. Baker Kevin P. Baker (= 1×) peers Bahija Jallal

Countries citing papers authored by Kevin P. Baker

Since Specialization

Citations

This map shows the geographic impact of Kevin P. Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin P. Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin P. Baker more than expected).

Fields of papers citing papers by Kevin P. Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin P. Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin P. Baker. The network helps show where Kevin P. Baker may publish in the future.

Co-authorship network of co-authors of Kevin P. Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin P. Baker. A scholar is included among the top collaborators of Kevin P. Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin P. Baker. Kevin P. Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Binnewies, Mikhail, Tiep Le, Joshua L. Pollack, et al.. (2019). Abstract C104: Therapeutic targeting of TREM2+ tumor-associated macrophages as a means of overcoming checkpoint inhibitor resistance. Molecular Cancer Therapeutics. 18(12_Supplement). C104–C104. 2 indexed citations

Barbee, Susannah D., Barbara Sennino, Mónica Macal, et al.. (2018). Abstract B005: FPT155, a novel therapeutic CD80-Fc fusion protein with potent antitumor activity in preclinical models. Molecular Cancer Therapeutics. 17(1_Supplement). B005–B005. 1 indexed citations

Pérez, José M., Emilie M.J. van Brummelen, E. Levchenko, et al.. (2017). Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM). Annals of Oncology. 28. v568–v569. 1 indexed citations

Bellovin, David I., Servando Palencia, Kevin Hestir, et al.. (2014). Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC. Cancer Research. 74(19_Supplement). 5449–5449. 1 indexed citations

Harding, Thomas C., Servando Palencia, Li Long, et al.. (2010). Abstract 2597: Preclinical efficacy of FP-1039 (FGFR1: Fc) in endometrial carcinoma models with activating mutations in FGFR2. Cancer Research. 70(8_Supplement). 2597–2597. 5 indexed citations

Harding, Thomas C., et al.. (2010). Preclinical Effi cacy of FP-1039 (FGFR1:Fc) in Endometrial Carcinoma Models with Activating Mutations in FGFR2. 2 indexed citations

Tolcher, Anthony W., et al.. (2009). Abstract A103: Preliminary results of a phase 1 study of FP-1039 (FGFR1:Fc), a novel antagonist of multiple fibroblast growth factor (FGF) ligands, in patients with advanced malignancies. Molecular Cancer Therapeutics. 8(12_Supplement). A103–A103. 5 indexed citations

Zhang, Hongbing, Kevin P. Baker, Ali Sadra, et al.. (2007). FP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis. Molecular Cancer Therapeutics. 6. 11 indexed citations

Halpern, Wendy, Patrick B. Lappin, Thomas A. Zanardi, et al.. (2006). Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects. Toxicological Sciences. 91(2). 586–599. 113 indexed citations

10.

Baker, Kevin P.. (2004). BLyS—an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmunity Reviews. 3(5). 368–375. 40 indexed citations

11.

Stohl, William, Samy Metyas, Gurtej S. Cheema, et al.. (2003). B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis & Rheumatism. 48(12). 3475–3486. 409 indexed citations

12.

Roschke, Viktor, Svetlana Sosnovtseva, Christopher D. Ward, et al.. (2002). BLyS and APRIL Form Biologically Active Heterotrimers That Are Expressed in Patients with Systemic Immune-Based Rheumatic Diseases. The Journal of Immunology. 169(8). 4314–4321. 205 indexed citations

13.

Gurney, Austin, Scot A. Marsters, Arthur Huang, et al.. (1999). Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Current Biology. 9(4). 215–218. 152 indexed citations

14.

Baker, Kevin P., et al.. (1998). Molecular cloning and characterization of human and murine DNase II. Gene. 215(2). 281–289. 54 indexed citations

15.

Pan, Clark Q., et al.. (1998). Cloning and characterization of an actin-resistant DNase I-like endonuclease secreted by macrophages. Gene. 215(2). 291–301. 41 indexed citations

16.

Sheridan, James P., Scot A. Marsters, Robert Pitti, et al.. (1997). Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors. Science. 277(5327). 818–821. 1474 indexed citations breakdown →

17.

Baker, Kevin P. & Gottfried Schatz. (1991). Mitochondrial proteins essential for viability mediate protein import into yeast mitochondria. Nature. 349(6306). 205–208. 236 indexed citations

18.

Baker, Kevin P. & David H. Boxer. (1991). Regulation of the chlA locus of Escherichia coli K12; involvement of molybdenum cofactor. Molecular Microbiology. 5(4). 901–907. 23 indexed citations

19.

Baker, Kevin P., et al.. (1990). A yeast mitochondrial outer membrane protein essential for protein import and cell viability. Nature. 348(6302). 605–609. 209 indexed citations

20.

Spiess, Martin, Christoph Handschin, & Kevin P. Baker. (1989). Stop-transfer activity of hydrophobic sequences depends on the translation system. Journal of Biological Chemistry. 264(32). 19117–19124. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact